Parkinson disease: An evolutionary perspective

Frontiers in Neurology

Volumn 8, Issue MAY, 2017, Pages

  Garcia Ruiz, Pedro J ^a   Espay, Alberto J ^b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Dopaminergic field; Evolutionary approach; Life expectancy; Parkinson disease; Physical activity

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR;

ARTICLE; CLINICAL FEATURE; CORPUS STRIATUM; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; ENERGY EXPENDITURE; HUMAN; KINESIOTHERAPY; LIFE EXPECTANCY; LIFESTYLE; NERVE DEGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PHYSICAL ACTIVITY; PREVALENCE; PROTEIN SECRETION; SURVIVAL RATE;

EID: 85019856228     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2017.00157     Document Type: Article

References (45)

1. Kalia LV, Lang AE. Parkinson's disease. Lancet (2015) 386:896-912. doi: 10.1016/S0140-6736(14)61393-3
2. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology (2004) 63:1240-4
3. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol (2006) 5:525-35. doi:10.1016/S1474-4422(06)70471-9
4. Savica R, Grossardt B, Bower J, Ahlskog E, Rocca W. Time trends in the incidence of Parkinson disease. JAMA Neurol (2016) 73:981-9. doi:10.1001/jamaneurol.2016.0947
5. Espay AJ, Brundin P, Lang AE. Precision medicine for disease modification in Parkinson disease. Nat Rev Neurol (2017) 13:119-26. doi:10.1038/nrneurol.2016.196
6. Gluckman PD, Hanson MA. Living with the past: evolution, development, and patterns of disease. Science (2004) 305:1733-6. doi:10.1126/science.1095292
7. García Ruiz PJ. Prehistory of Parkinson's disease. Neurologia (2004) 19:735-7
8. Liu CC, Li CY, Lee PC, Sun Y. Variations in incidence and prevalence of Parkinson's disease in Taiwan: a population-based nationwide study. Parkinsons Dis (2016) 2016:8756359. doi:10.1155/2016/8756359
9. Chen L, Brown RE, McKenna JT, McCarley RW. Animal models of narcolepsy. CNS Neurol Disord Drug Targets (2009) 8:296-308. doi:10.2174/187152709788921717
10. Schwartz M, Lamb CR, Brodbelt DC, Volk HA. Canine intracranial neoplasia: clinical risk factors for development of epileptic seizures. J Small Anim Pract (2011) 52:632-7. doi:10.1111/j.1748-5827.2011.01131.x
11. McGreevy JW, Hakim CH, McIntosh MA, Duan D. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech (2015) 8:195-213. doi:10.1242/dmm.018424
12. Hamilton T, Glass E, Drobatz K, Agnello KA. Severity of spinal cord dysfunction and pain associated with hydrated nucleus pulposus extrusion in dogs. Vet Comp Orthop Traumatol (2014) 27:313-8. doi:10.3415/VCOT-13-06-0076
13. Vernier P, Moret F, Callier S, Snapyan M, Wersinger C, Sidhu A. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system. Ann N Y Acad Sci (2004) 1035:231-49. doi:10.1196/annals.1332.015
14. Aron Badin R, Vadori M, Cozzi E, Hantraye P. Translational research for Parkinson's disease: the value of pre-clinical primate models. Eur J Pharmacol (2015) 759:118-26. doi:10.1016/j.ejphar.2015.03.038
15. Glassa D, Arnold S. Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology. Alzheimers Dement (2012) 8:343-51. doi:10.1016/j.jalz.2011.05.2408
16. Collier TJ, Lipton J, Daley BF, Palfi S, Chu Y, Sortwell C, et al. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis (2007) 26:56-65. doi:10.1016/j.nbd.2006.11.013
17. Hurley PJ, Elsworth JD, Whittaker MC, Roth RH, Redmond DE Jr. Aged monkeys as a partial model for Parkinson's disease. Pharmacol Biochem Behav (2011) 99:324-32. doi:10.1016/j.pbb.2011.05.007
18. Matsuda W, Furuta T, Nakamura KC, Hioki H, Fujiyama F, Arai R, et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci (2009) 29:444-53. doi:10.1523/JNEUROSCI.4029-08.2009
19. Bolam JP, Pissadaki EK. Living on the edge with too many mouths to feed: why dopamine neurons die. Mov Disord (2012) 27:1478-83. doi:10.1002/mds.25135
20. Pissadaki EK, Bolam JP. The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front Comput Neurosci (2013) 7:13. doi:10.3389/fncom.2013.00013
21. Rein R, Bril B, Nonaka T. Coordination strategies used in stone knapping. Am J Phys Anthropol (2013) 150:539-50. doi:10.1002/ajpa.22224
22. Hikosaka O, Nakamura K, Sakai K, Nakahara H. Central mechanisms of motor skill learning. Curr Opin Neurobiol (2002) 12:217-22. doi:10.1016/S0959-4388(02)00307-0
23. Ungerleider LG, Doyon J, Karni A. Imaging brain plasticity during motor skill learning. Neurobiol Learn Mem (2002) 78:553-64. doi:10.1006/nlme.2002.4091
24. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely, and Jones (1817)
25. García de Yébenes J, García Ruiz P. Description of camptocormia in Parkinson disease by Francisco de Zurbarán. Neurologia (2000) 15:265-6
26. Garcia Ruiz PJ, Ruiz Ezquerro JJ, Garcia Torres A, Fanjul S. Ancient descriptions of movement disorders: Cathedral el Burgo de Osma (Soria, Spain). J Neurol (2006) 253:731-4. doi:10.1007/s00415-006-0100-8
27. Gowers WR. Paralysis agitans. In: Gowers WR, editor. A Manual of Diseases of the Nervous System. (Vol. II), London: J &A Churchill (1886). p. 589-608
28. Kinnier Wilson SA. Paralysis agitans. In: Bruce N, editor. Neurology by Kinnier Wilson. (Vol. II), London: Edward Arnold & Co. (1940). p. 787-804
29. Young AW. A clinical analysis of an extrapyramidal syndrome; paralysis agitans and postencephalitic parkinsonism. J Neurol Psychopathol (1927) 8:9-18. doi:10.1136/jnnp.s1-8.29.9
30. Garland HG. Parkinsonism. Br Med J (1952) 1:153-5. doi:10.1136/bmj.1.4750.153
31. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology (2007) 68:384-6. doi:10.1212/01.wnl.0000247740.47667.03
32. Rocca WA, Bower JH, McDonnell SK, Peterson BJ, Maraganore DM. Time trends in the incidence of parkinsonism in Olmsted County, Minnesota. Neurology (2001) 57:462-7. doi:10.1212/WNL.57.3.462
33. Wickremaratchi MM, Perera D, O'Loghlen C, Sastry D, Morgan E, Jones A, et al. Prevalence and age of onset of Parkinson's disease in Cardiff: a community based cross sectional study and meta-analysis. J Neurol Neurosurg Psychiatry (2009) 80:805-7. doi:10.1136/jnnp.2008.162222
34. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol (2016) 15:1257-72. doi:10.1016/S1474-4422(16)30230-7
35. O'Keefea JH, Vogelb R, Laviec CJ, Cordain L. Exercise like a hunter-gatherer: a prescription for organic physical fitness. Prog Cardiovasc Dis (2011) 53:471-9. doi:10.1016/j.pcad.2011.03.009
36. Mattson MP. Lifelong brain health is a lifelong challenge: from evolutionary principles to empirical evidence. Ageing Res Rev (2015) 20:37-45. doi:10.1016/j.arr.2014.12.011
37. La Hue S, Comella C, Tanner CM. The best medicine? The influence of physical activity and inactivity on Parkinson's disease. Mov Disord (2016) 31:1444-54. doi:10.1002/mds.26728
38. Corcos DM, Robichaud JA, David FJ, Leurgans SE, Vaillancourt DE, Poon C, et al. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord (2013) 28:1230-40. doi:10.1002/mds.25380
39. David FJ, Robichaud JA, Leurgans SE, Poon C, Kohrt WM, Goldman JG, et al. Exercise improves cognition in Parkinson's disease: the PRET-PD randomized, clinical trial. Mov Disord (2015) 30:1657-63. doi:10.1002/mds.26291
40. Yang F, Trolle Lagerros Y, Bellocco R, Adami HO, Fang F, Pedersen NL, et al. Physical activity and risk of Parkinson's disease in the Swedish National March Cohort. Brain (2015) 138:269-75. doi:10.1093/brain/awu323
41. Klein C, Rasinska J, Empl L, Sparenberg M, Poshtiban A, Hain EG, et al. Physical exercise counteracts MPTP-induced changes in neural precursor cell proliferation in the hippocampus and restores spatial learning but not memory performance in the water maze. Behav Brain Res (2016) 307:227-38. doi:10.1016/j.bbr.2016.02.040
42. Real CC, Ferreira AF, Chaves-Kirsten GP, Torrão AS, Pires RS, Britto LR. BDNF receptor blockade hinders the beneficial effects of exercise in a rat model of Parkinson's disease. Neuroscience (2013) 237:118-29. doi:10.1016/j.neuroscience.2013.01.060
43. Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology (2011) 77:288-94. doi:10.1212/WNL.0b013e318225ab66
44. da Silva PG, Domingues DD, de Carvalho LA, Allodi S, Correa CL. Neurotrophic factors in Parkinson's disease are regulated by exercise: evidence-based practice. J Neurol Sci (2016) 363:5-15. doi:10.1016/j.jns.2016.02.017
45. Voss MW, Erickson KI, Prakash RS, Chaddock L, Kim JS, Alves H, et al. Neurobiological markers of exercise-related brain plasticity in older adults. Brain Behav Immun (2013) 28:90-9. doi:10.1016/j.bbi.2012.10.021